Thur 3 November 2011
Hosted by: Fasken Martineau
Organised by: Asia-Pacific Technology Network
Chair
Speakers
China is the world's third largest pharmaceutical market and is poised to become the lead destination for international biopharma outsourcing. For the moment, the Chinese "biosimilars" industry is relatively weak, but the development capabilities of these companies is growing exponentially, at least in part due to the return of highly trained nationals. This seminar will look at China's potential in biosimilars and the wider biotechology sphere. It will raise questions about how these emerging companies can fund themselves to reach the requisite size and quality. It will then look at prospects for British companies.
Location: Fasken Martineau, 17 Hanover Square London W1S 1HU
Nearest tube station: Oxford Circus
Timing: Registration from 17:00: seminar from 17:30 - 19.15 (followed by refreshments)
Pricing:
To Register your interest- please send your details (name, institutional affiliation, email address, phone number - and the category you come under) to biz22@aptn.org
Douglas B. Andrews
A senior multinational healthcare industry executive and entrepreneur, with 30 years’ experience in global pharmaceutical and medical technology markets, including sales & marketing, product licensing, M&A, organizational start-up, country and regional management. Founded and raised venture capital for the first European „virtual“ generic pharmaceutical company. Subsequently created a holding company to acquire dermatology companies/products in Europe and the USA. Current venture focuses on healthcare products and technology trading among China, Europe and the USA.
Founder/CEO Stravencon Ltd 2006-Present
Stravencon Ltd. (www.stravencon.com) provides a product and technology trading platform for Chinese life science companies to enter the regulated markets of Europe and North America. Negotiated 50/50 Joint Venture with a top 10 Chinese pharmaceutical company which will be the exclusive conduit for that firm’s products to enter the European market. Signed MOU’s with four other leading Chinese biopharmaceutical companies for exclusive European marketing and distribution rights covering a broad range of specialty generics, including anti-infectives, oncology and associated generics and biosimilars. Negotiating European marketing rights with major Chinese suppliers of diagnostic and class 2/3 medical devices. Also assisting European and American healthcare companies to contract with development and marketing partners in China.
Co-Founder/CEO Mercuriah Ltd 2007-9
Senior Advisor, National Bank of Dubai 2008-9
Founder/CEO Consilient Health Ltd 2000-2006
Assorted Roles, Schering-Plough Corporation 1979-2000
Bruce Murdoch
Bruce has over 35 years of experience in the fields of General Management, Marketing and Corporate M&A within the global life science and pharmaceutical industry. Since 1975 he has held a number of Senior Management positions with Rhone-Poulenc (1975-1980), AstraZeneca (1980-1990), Pharmacia (1990-1996) and Schering-Plough (1996-2002) within UK and Asian markets including Japan. He was also involved in the early entry of the pharmaceutical industry into China with a number of joint-ventures in 1988-1990. From 2002 he was Senior Vice-President of Bioaccelerate Inc in London and CEO of a small biotechnology start-up company called Genaderm Ltd. In 2006 Bruce joined Avesthagen Pvt Ltd, a Systems Biotechnology company based in Bangalore, India as Chief Business Officer. They are currently developing a number of “Biosimilars” for the world markets. In 2009 he returned to London, UK to join Stravencon Limited, a UK based pharmaceutical company that specialises in product trading and advisory work between EU and China. He graduated from Nottingham University in 1971 with an Honours Degree in Biological Sciences with Statistics. He has been Chairman of various Pharmaceutical branches of IFPMA and PhRMA. He is currently a member of the Institute of Directors and the China British Business Council in UK.
Jo Pisani
is a Partner in the Strategy team of PricewaterhouseCoopers. She has thirteen years of industry experience in the pharmaceuticals, energy, petrochemicals, and fast-moving consumer goods industries with BP and SmithKline Beecham where she held positions in the engineering, operations, IT, and commercial functions. Before joining PwC, she spent three years with Booz&Co, a strategic management consultancy where she focused on strategic issues in the pharmaceuticals and energy sectors.
Jo assists clients developing strategy, supporting deals and conducting valuations. Her client include Big Pharma, biotech, generics, OTC, contract manufacturers, contract research organisations, ministries of health, private equity and banks.
Jo has an MBA (with distinction) from Warwick Business School and is a Chartered Engineer. She is fluent in English and French and has a working knowledge of Thai and Dutch.
Dr Jesse Schulman
is an experienced investment banker and transaction manager with broad experience in corporate partnering, fundraising and M&A transactions in biotechnology and pharmaceuticals. He has worked in both the biopharmaceutical and small molecule areas, and his transactional experience includes product licensing, company and assets sales, and VC fundraising.
Dr Schulman earned a BA in mathematics at Columbia University and a PhD in Neurosciences at UCSD and the Salk Institute, specializing in neuropharmacology. He has worked with companies and products in a wide range of therapy areas including cancer and metabolic diseases, neurological diseases, psychiatric disorders and pain, and has also worked in medical devices, including molecular diagnostics and personalised medicine. He is an expert provider of the full range of support services required for a successful transaction, including preparation of offering documents, market analysis, deal modelling and valuation, transaction marketing, management of pharma due diligence and deal process management. He brings extensive contact networks in pharmaceutical and biotechnology business development, corporate development and venture capital, as well valuable expertise in structuring, evaluating and executing complex cross-border corporate partnering and staged divestment transactions.
Transactions in which Dr Schulman has played a central role include the sale of French cancer specialty pharma company OPi for €110 million, the licensing of EUSA Pharma’s Firdapse for neurological disorders to Biomarin, the licensing of Alizé Pharma’s preclinical diabetes peptide program to Eli Lilly and the disposal of German firm Novosom's siRNA delivery assets. Other strategic consulting, documentation and support roles include assisting on the US $45.5 million fundraising by Zelos Pharma for its clinical-stage peptide for osteoporosis, supporting a seed stage fundraising for Phiilogene’s preclinical VEGF isoform antibody project, and many others. Current assignments include Cumberland Pharma (out-licensing of its injectable ibuprofen) and UK spin-out Canbex (out-licensing of its preclinical MS spasticity program).